Finding Reveals Broader Role Of Telomerase Enzyme, Suggesting New Target For Extending Life Span Of Cell

April 02, 1999

Researchers at UC San Francisco have determined that telomerase - the enzyme brought to fame last year when scientists demonstrated that its insertion into normal cells extended the healthy life span of the cells indefinitely - can wield its power in an unexpected way.

The finding, reported in the current issue of Proceedings of the National Academy of Sciences, could bolster efforts aimed at manipulating the enzyme for therapeutic purposes - whether to prompt cell division in order to replenish stocks of healthy cells, as is needed in bone marrow transplants, or to interrupt the excessive cell proliferation that occurs in cancer cells.

Telomerase synthesizes telomeres, snippets of DNA on the ends of chromosomes that function in part like the plastic tips on the ends of shoelaces, preventing the gene-bearing, threadlike spindles from unraveling. With each cycle of cell division, the tips of telomeres drop off, until the chemical bookends become so eroded that the chromosomes become unstable, a condition that signals cells to stop dividing. This natural control on cell division is known as the Hayflick limit. Cancers develop when cells increasingly ignore or override such signals of chromosome impairment.

Until now, evidence has suggested that the ability of telomerase to extend the life span of cells lay in its capacity to lengthen telomeres.

In the current study, a collaboration by the laboratories of Elizabeth Blackburn, PhD, chair of the Department of Microbiology and Immunology at UCSF and Nobel laureate J. Michael Bishop, MD, chancellor of UCSF, researchers have determined that telomerase can extend the life span of human fibroblast cells without lengthening telomeres. The telomerase enzyme, they discovered, caps the ends of telomeres and, in so doing, somehow contributes to telomere, and thus, chromosome, stability - regardless of telomere length.

"The finding was quite extraordinary," said Blackburn. "Previous evidence has suggested that telomere length is crucial to determining the life span of cells. But in cells in which we activated the telomerase enzyme, we observed cells thriving despite the fact that their telomeres were very short."

Furthermore, the telomeres of these experimental cells were shorter than those in a set of cells lacking the activated enzyme. These comparison cells had predictably stopped dividing once their telomeres had substantially eroded.

"The combination of somewhat shortened telomeres and inactivated telomerase appears to be the devastating blow," said Blackburn. "The telomerase cap is somehow making a contribution to telomere - and thus chromosome - stability."

The finding does not suggest that telomere length is not important to cell life span. Rather, it reveals a new factor contributing to chromosome stability, and offers a new direction for potentially manipulating the enzyme for therapeutic purposes.

Blackburn's co-discovery of the telomerase enzyme in 1985 spawned a whole field of inquiry into the possibility that the enzyme could be activated, or de-activated, to prolong cell life and combat cancer. For while the enzyme is "turned off" in many normal cells in humans, researchers are able to activate it by inserting the gene for its protein component, known as TERT into cells. In the current study, activation of telomerase extended the life span of experimental cells, apparently indefinitely, and reduced the frequency of abnormal chromosomes. Unexpectedly, however, the life span extension occurred under conditions in which the cells' telomeres were very short.

The researchers conducted their study in human fibroblast cells from which critical molecular safety checkpoints had been removed, setting the cells up to ignore warning signs of chromosome instability, and to begin dividing excessively. While not full-fledged cancer cells, since some molecular checkpoints remained in check, these cells, in comparison to the normal ones, were susceptible to excessive proliferation. Adding telomerase removed the last barrier to immortal growth of these precancerous cells, revealing the enzyme to be a cancer-romoting factor in cells already part way along the road to malignancy.

Blackburn's lab had previously observed the phenomenon of cell immortality and shortened telomeres in two yeast species, and she attributes the researchers' recent success in revealing the event in human cells to timing. Telomerase-telomere interaction produces a continuous ebb and flow of telomere length, with telomerase continuously attempting to counter the erosion of telomeres. So while telomeres generally get longer in the company of telomerase, in the current study, the researchers managed to catch the molecular sway at the unusual moment when telomeres were very short and telomerase's role was needed to kick-in to stabilize the chromosome tips, thus revealing telomerase's unique contribution.

"It just happened we caught the two factors in the balance where telomeres were getting shorter even though telomerase was there. The enzyme just wasn't keeping up with the telomere loss," said Blackburn.

"Chromosomes appear to have three or four methods of buttressing themselves," said Blackburn, "and these methods seem to cooperate. If one device is taken away, the chromosome remains stable. But if a second one is taken away, you start to see an effect. This is why the capping role of telomerase isn't revealed until the chromosomes get fairly short. When the chromosomes' telomeres are still very long, they do just fine stabilizing themselves by other means."

The question now, said Blackburn, is how the telomerase works in its newly revealed capacity. "We want to understand what it is about the act of polymerization [when the enzyme replicates the telomeric DNA tips] that contributes to the chromosomes' stability. We'll be looking at mutants in yeast and human cells to try to figure out this mechanism."

The explanation could enable researchers to make the most of the still-theoretical process of replenishing healthy cells via telomerase manipulation. Traditional thinking suggested that it would take a long time (many tens of cell-replication rounds) for telomerase to build up the length of telomeres to an effective length.

"Now we know it could probably be done very quickly, providing a quick fix," said Blackburn. "It would be nice to have a burst of telomerase, where we wouldn't have to wait to build back telomeres."

Being able to quickly replenish telomeres would be particularly helpful in situations where it is necessary to build back a sufficient supply of healthy cells quickly, as during bone marrow transplants.

"Telomerase might be able to replenish telomeres quickly," said Blackburn, "and then enable researchers to turn back off the telomerase enzyme again so wouldn't do any harm and start causing risks of cancer."

The study was led by postdoctoral fellow He Wang, Ph.D., in Blackburn's lab, and Jiyue Zhu, in Bishop's lab.

The UCSF study was funded by the National Institutes of Health, the G.W. Hooper Foundation and the Leukemia Society of America.
-end-


University of California - San Francisco

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.